Safety and efficacy of dexamethasone intravitreal implant (Ozurdex) for the treatment of persistent macular edema secondary to retinal vein occlusion in eyes previously treated with anti-vascular endothelial growth factors

Current Drug Safety

Volumn 10, Issue 2, 2015, Pages 145-151

  Tservakis, Ioannis ^a   Koutsandrea, Chryssanthi ^a   Papaconstantinou, Dimitrios ^a   Paraskevopoulos, Theodore ^a   Georgalas, Ilias ^a  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; VASCULOTROPIN ANTIBODY; ANTIINFLAMMATORY AGENT; DRUG IMPLANT; ENDOTHELIAL CELL GROWTH FACTOR;

ADULT; AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; BIOMICROSCOPY; BRANCH RETINAL VEIN OCCLUSION; CATARACT; CATARACT EXTRACTION; CATARACTOGENESIS; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; INTRAVITREAL IMPLANT; MACULAR EDEMA; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; SIDE EFFECT; TONOMETRY; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG IMPLANT; MANOMETRY; MIDDLE AGED; PATHOLOGY; RETINA VEIN OCCLUSION; VERY ELDERLY; VISION TEST; VITREOUS BODY;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; DEXAMETHASONE; DRUG IMPLANTS; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; MACULAR EDEMA; MALE; MANOMETRY; MIDDLE AGED; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; VISION TESTS; VISUAL ACUITY; VITREOUS BODY;

EID: 84930521382     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574886309666140805142245     Document Type: Article

References (38)

1. Hayreh S. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 2005; 24: 493-519.
2. Joussen AM, Gardner TW, Kirchhof B, Ryan SJ. Retinal Vascular Disease. Springer-Verlag 2007: 443-66.
3. Shahsuvaryan ML. Therapeutic potential of intravitreal pharmacotherapy in retinal vein occlusion. Int J Ophthalmol 2012; 5: 759-770.
4. Gutman FA, Zegarra H. The natural course of temporal retinal branch vein occlusion. Trans Am Acad Ophthalmol Otolaryngol 1974; 78: 178-192.
5. Michels RG, Gass JD. The natural course of retinal branch vein obstruction. Trans Am Acad Ophthalmol Otolaryngol 1974; 78: 166-177.
6. Zegarra H, Gutman FA, Conforto J. The natural course of central retinal vein occlusion. Ophthalmology 1979; 86: 193-42.
7. Hayreh SS. Classification of central retinal vein occlusion. Ophthalmology 1983; 90, 458-74.
8. Gutman FA, Zegarra H. Macular edema secondary to occlusion of the retinal veins. Surv Ophthalmol 1984; 28: 462-70.
9. Gardner TW, Antonetti DA, Barber AJ, Lieth E, Tarbell JA. The molecular structure and function of the inner blood–retinal barrier. Ophthalmology 1999; 97: 229-237.
10. Vinores SA, Derevjanik NL, Ozaki H, Okamoto N, Campochiaro PA. Cellular mechanisms of blood–retinal barrier dysfunction in macular edema. Ophthalmology 1999; 97: 217-228.
11. Marieb E, Hoehn K. Human Anatomy and Physiology (7th edn). Pearson International Edition, 2007.
12. Pieramici DJ, Rabena M, Castellarin AA, et al. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology 2008; 115: e47-54.
13. Scholl S, Kirchhof J, Augustin AJ, et al. Pathophysiology of Macular Edema. Ophthalmologica 2010; 224 (suppl 1): 8-15.
14. Cheng CY. Biology and Regulation of Blood-Tissue Barriers (1st edn) Springer 2012.
15. Noma H, Minamoto H, Funatsu H, et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefe’s Arch Clin Exp Ophthalmol 2006; 244: 309-315.
16. Noma H, Funatsu H, Harino S, et al. Vitreous inflammatory factors in macular edema with central retinal vein occlusion. Jpn J Ophthalmol 2011; 55: 248-255.
17. Noma H, Funatsu H, Mimura T, Eguchi S, Hori S. Soluble Vascular Endothelial Growth Factor Receptor-2 and Inflammatory Factors in Macular Edema with Branch Retinal Vein Occlusion. Am J Ophthalmol 2011; 152, 669-77.
18. McIntosh RL, Mohamed Q, Saw SM, Wong TY. Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007; 114: 835-54.
19. Mohamed Q, McIntosh RL, Saw SM, Wong TY. Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007; 114: 507-1.
20. Haller JA, Gillies M, Li XY. Dexamethasone Intravitreal Implant in Patients with Macular Edema Related to Branch or Central Retinal Vein Occlusion. Ophthalmology 2011; 118: 2453-2460.
21. Sharareh B, Gallemore RP, Taban M, Onishi S, Wallsh J. Recalcitrant macular edema after intravitreal bevacizumab is responsive to an intravitreal dexamethasone implant in retinal vein occlusion. Retina 2013; 33, 1227-31.
22. Robinson ΜR, Whitcup SM. Pharmacologic and clinical profile of dexamethasone intravitreal implant. Expert Rev. Clin Pharmacol 2012; 5: 629-647.
23. Kuppermann BD, Blumenkranz MS, Haller JA. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007; 125: 309-17.
24. Haller JA, Bandello F, Belfort R Jr. et al. Randomized, shamcontrolled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117:1134-146 e1133.
25. Lucentis Summary of Product Characteristics available online at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_P roduct_Information/human/000715/WC500043546.pdf.
26. Kleinman ΑΕ, Baffi JZ, Ambati J. The Multifactorial Nature of Retinal Vascular Disease. Ophthalmol 2010; 224(suppl 1):16-24.
27. Brown DM, Campochiaro PA, Singh RP. Ranibizumab for Macular Edema following Central Retinal Vein Occlusion. Ophthalmology 2010; 117:1124-133.
28. Campochiaro PA, Saroj N, Heier JS, et al. Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion. Ophthalmology 2010; 117:1102-112.
29. Augustin A, Holz FG, Haritoglou C. Presented at EVER 2012 congress, Nice 2012, France. Oct 10-13.
30. Coscas G, Loewenstein A, Augustin A. ‘Management of Retinal Vein Occlusion – Consensus Document’ Ophthalmologica 2011; 226: 4-28.
31. Pommier S, Meyer F. RE-MI-DO Study: resultats of a multicenter study of dexamethasone implantation in eyes with macular oedema in retinal vein occlusion. Acta Ophthalmol 2012; 90: 0-0.
32. Capone A, Singer MA, Dodwell DG. Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (SHASTA STUDY), Retina 2014; 32(2): 342-51.
33. Querques L, Querques G, Lattanzio R, et al. Repeated Intravitreal Dexamethasone Implant (Ozurdex) for Retinal Vein Occlusion. Ophthalmolgica 2012; DOI: 10.1159/000342160.
34. Allergan; data on file – fractured implants 2003.
35. Meyer LM, Schonfeld CL. Secondary Glaucoma After Intravitreal Dexamethasone 0.7 mg Implant in Patients with Retinal Vein Occlusion: A one-Year Follow-Up. J Ocul Pharmacol therapeut 2013; 29(6): 560-65.
36. Rishi P, Mathur G, Rishi E. Fractured Ozurdex implant in the vitreous cavity. Ind J Ophthalmol 2012; 60: 337-38.
37. Donmez O, Parlak M, Yaman A, Saatci AO. Splitting of a Dexamethasone Implant (Ozurdex) following the Injection. Ophthalmol Med 2013; ID 247949.
38. Roy R, Hedge S. Split Ozurdex implant: a caution. Canadian J Ophthalmol 2013; 48: 15-16.